Year of pediatric labeling Agent Indication COG study
2005 Nelarabine T-cell leukemia/lymphoma P9673
2006 PEG asparaginase Acute lymphoblastic leukemia 1962
2011 Erwinia asparaginase Acute lymphoblastic leukemia AALL07P2
2011 2013
Imatinib
Ph+ chronic myelogenous leukemia Ph+ acute lymphoblastic leukemia AAML0123 AALL0031
2015 Dinutuximab Neuroblastoma ANBL0032
2017 Pembrolizumab Hodgkin lymphoma, MSI-H, TMB-H ADVL1621
2018 SC-PEG asparaginase Acute lymphoblastic leukemia AALL07P4
2018 Blinatumomab Acute lymphoblastic leukemia AALL1121
2019 Dasatinib Ph+ acute lymphoblastic leukemia AALL1122
2020 Gemtuzumab ozogamicin Acute myelogenous leukemia AAML0531
2021 Liposomal daunorubicin/cytarabine Acute myelogenous leukemia AAML1421
2021 Recombinant Erwinia asparaginase Acute lymphoblastic leukemia AALL1931
2021 Rituximab CD20+ non-Hodgkin lymphoma ANHL1131
2021 2022
Crizotinib
Anaplastic large cell lymphoma, Inflammatory myofibroblastic tumor
ADVL0912
2022 Brentuximab Hodgkin lymphoma AHOD1331